Structured evidence table for Omega-3, generated from 3 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Omega-3 | Efficacy of phospholipid-bound omega-3 versus standard omega-3 in patients with hypertriglyceridemia: a randomized clinical trial. | 2 | Urina-Triana M (2026) | Efficacy of phospholipid-bound omega-3 versus standard omega-3 in patients with hypertriglyceridemia: a randomized clinical trial. |
| Omega-3 | 9 10 Given the modest efficacy of standard interventions, interest in well-tolerated, low-risk alternatives is increasing (). | 3 | Fleig Katharina (2026) | Omega-3 fatty acids in mental disorders: from neurobiological and metabolic mechanisms to therapeutic potential |
| Omega-3 | Conversely, omega-3 PUFAs eicosapentaenoic acid (EPA; 20:5ω3), docosapentaenoic acid (DPA; 22:5ω3), and docosahexaenoic acid (DHA; 22:6ω3) are predominantly found in fatty marine fish and algae (,). | 3 | Fleig Katharina (2026) | Omega-3 fatty acids in mental disorders: from neurobiological and metabolic mechanisms to therapeutic potential |
| Omega-3 | Evidence suggests that ALA may have a neuroprotective and anti-inflammatory potential concerning systemic, neuroinflammatory, and mental disorders (). | 3 | Fleig Katharina (2026) | Omega-3 fatty acids in mental disorders: from neurobiological and metabolic mechanisms to therapeutic potential |
| Omega-3 | 1 2 3 5 5 Mental disorders currently rank among the leading contributors to the global burden of disease, posing substantial individual and societal challenges (,). | 3 | Fleig Katharina (2026) | Omega-3 fatty acids in mental disorders: from neurobiological and metabolic mechanisms to therapeutic potential |
| Omega-3 | Consequently, identifying modifiable risk factors to prevent or delay cognitive decline is of critical public health importance [,]. | 4 | Liao Zheng-Bin (2026) | The association between omega-3 supplementation and cognitive decline in older adults |
| Omega-3 | By elucidating these specific neurobiological pathways, we aim to provide clinical evidence that informs the debate regarding the role of omega-3 fatty acids supplementation in slowing cognitive decline. | 4 | Liao Zheng-Bin (2026) | The association between omega-3 supplementation and cognitive decline in older adults |
| Omega-3 | 29 30 31 This study employed three commonly used cognitive scales to assess longitudinal trajectories associated with omega-3 supplementation: the Mini-Mental State Examination (MMSE), the Alzheimer’s Disease Assessment Scale–Cognitive Subscale 13 (ADAS-Cog13), and the Clinical Dementia Rating–Sum of Boxes (CDR-SB). | 4 | Liao Zheng-Bin (2026) | The association between omega-3 supplementation and cognitive decline in older adults |
| Omega-3 | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 in vivo Alzheimer’s disease (AD), the leading cause of dementia, imposes a growing global public health burden []. | 4 | Liao Zheng-Bin (2026) | The association between omega-3 supplementation and cognitive decline in older adults |
Source documents